// App-Quantinova.ai

1469 : Bone Mineral Density At Diagnosis Determines Fracture Rate in Children Treated According to the DCOG-ALL9 Protocol

Researchers

Presenter

  • Rob Pieters

Principal Investigators

  • Wim C.J. Hop

  • Marry M. van den Heuvel-Eibrink

  • Jan C. Roos

  • Inge M. van der Sluis

  • Jos P.M. Bokkerink

  • Jan A. Leeuw

  • Marrie C. A. Bruin

  • Wouter J.W. Kollen

  • Anjo J.P. Veerman

  • Hester A. de Groot-Kruseman

Medical Centers

  • Dutch Childhood Oncology Group, The Hague, Netherlands.

  • Department of Medical Statistics, Leiden University Medical Center, Leiden, Netherlands

  • Paediatric Immunology and Rheumatology, University Medical Centre Utrecht - Wilhelmina Children's Hospital, Utrecht, Netherlands

  • Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

  • Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

  • Department of Pediatric Oncology, Beatrix Children's Hospital, University of Groningen, Groningen, Netherlands

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

  • Department of Biostatistics, Erasmus University Medical Center, Rotterdam, Netherlands

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Department of Pediatric Oncology/ Hematology, University Medical Center St Radboud, Nijmegen, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Bone Mineral Density

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved